TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

ADVIL DUAL ACTION WITH ACETAMINOPHEN

ACETAMINOPHEN
Approved 2020-02-28
1
Indication
--
Phase 3 Trials
6
Years on Market

Details

Status
Over-the-counter
First Approved
2020-02-28
Routes
ORAL
Dosage Forms
TABLET

Companies

Active Ingredient: ACETAMINOPHEN , IBUPROFEN

ADVIL DUAL ACTION WITH ACETAMINOPHEN Approval History

Loading approval history...

What ADVIL DUAL ACTION WITH ACETAMINOPHEN Treats

1 FDA approvals

Originally approved for its first indication in 2020 .

  • Other (1)
๐Ÿ”ฌ

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
โญ

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
๐Ÿ“Š

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

ADVIL DUAL ACTION WITH ACETAMINOPHEN FDA Label Details

Pro

ADVIL DUAL ACTION WITH ACETAMINOPHEN Patents & Exclusivity

Latest Patent: Jul 2041

Patents (1 active)

US11918693 Expires Jul 9, 2041
Source: FDA Orange Book

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.